latest news releases from the newsroom
Medicis Pharmaceutical Corporation
Reloxin Agreement Between Ipsen and Medicis Becomes Effective
PARIS and SCOTTSDALE, Ariz., March 20, 2006 (PRIMEZONE) -- Ipsen (Eurolist by Euronext(TM): IPN FP) and Medicis (NYSE:MRX) today announced that the agreement whereby Ipsen Ltd, a wholly-owned subsidiary of Ipsen ("Ipsen"), grants Aesthetica Ltd, a wholly-owned subsidiary of Medicis ("Medicis"), rights to develop, distribute and commercialize Ipsen's botulinum toxin product in the United States, Canada and Japan for aesthetic use by physicians is now effective. The product is commonly referred to as Reloxin(R) in the U.S. aesthetic market and Dysport(R) for medical and aesthetic markets outside the U.S. The product is not currently approved for use in the U.S. Ipsen has recovered its rights to Reloxin(R) at the time of this announcement.
H&Q Asia Pacific
H&Q Asia Pacific Successfully Divests GoRemote Internet Communications, Inc. in Sale to iPass Inc.
PALO ALTO, Calif., March 20, 2006 (PRIMEZONE) -- H&Q Asia Pacific ("H&QAP") today announced that it has successfully divested its holdings in GoRemote Internet Communications, Inc. ("GRIC"), a leading provider of secure, managed broadband network services to large and mid-size distributed enterprises and services providers worldwide. H&QAP's divestment in GRIC was completed as a result of iPass Inc.'s (Nasdaq:IPAS) acquisition of GRIC, which closed in February 2006.
H&Q Asia Pacific Retains MarketcomPR for U.S. Communications
GREENWICH, Conn., March 20, 2006 (PRIMEZONE) -- MarketcomPR today announced that it has been selected by H&Q Asia Pacific, a leading private equity firm that invests throughout the Asia Pacific region, as lead agency for communications in the U.S. In that role, MarketcomPR will develop communications initiatives to increase awareness of H&Q Asia Pacific among key audiences in the U.S., Europe and the Middle East including potential investors, deal sources, and potential partners.
StockGuru.com Announces Exclusive Executive Interview With James Hergott of Imperia Entertainment
DALLAS, March 20, 2006 (PRIMEZONE) -- John Pentony, Publisher of StockGuru.com, announced today that the web site has released a new executive interview with James Hergott, President of Imperia Entertainment, In. (Pink Sheets:IPRE). Imperia Entertainment is a company which has emerged as a player in the area of independent film production and distribution, once monopolized by the major film studios. In conjunction with its distribution subsidiary, Imperia International Distribution, the company engages in investing in and producing and distributing full-length feature films.
Dow Jones Indexes
STOXX to Launch Indexes Tracking Key Real Estate Markets
ZURICH, Switzerland, March 20, 2006 (PRIMEZONE) -- STOXX Ltd., the leading European index provider, today launched three real estate indexes, the Dow Jones STOXX 600 Real Estate Index, the Dow Jones STOXX Americas 600 Real Estate Index and the Dow Jones STOXX Asia/Pacific 600 Real Estate Index, which track the performance of the top real estate investment trusts (REITs) and real estate holding & development stocks in Europe, the Americas and Asia/Pacific.
Fougera Marks Sixth Snakebite Season with CroFab Crotalidae Polyvalent Immune Fab (Ovine)
MELVILLE, N.Y., March 20, 2006 (PRIMEZONE) -- Fougera(r) Inc. has marked its sixth season of supplying CroFab(r) Crotalidae Polyvalent Immune Fab (Ovine), the primary antivenom for snakebites from the crotalid snake species common to the United States. The term crotalid is used to describe the Crotalinae subfamily (formerly known as Crotalidae) of venomous snakes that comprise the vast majority of common North American snakes, including rattlesnakes, copperheads and cottonmouths/water moccasins. When CroFab was launched in 2001, it was the first new snakebite antivenom to be made available in nearly 50 years. CroFab is currently the only widely available antivenom for crotalid snakes.
Amgen and Bird Flu from DonHarrold.net
SHREVEPORT, La., March 20, 2006 (PRIMEZONE) -- Don Harrold (IARD #119079, www.donharrold.net), rates Amgen (Nasdaq:AMGN), Transocean (NYSE:RIG), Texas Instruments (NYSE:TXN), and Johnson & Johnson (NYSE:JNJ).